Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

9 March 2023

Telix today announces presentations from the Company’s carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held in Milan from 10 – 13 March 2023.

Further data from Telix’s completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) ( Identifier: NCT03849118) will be presented in a “Game Changing” oral session.

Game Changing sessions are reserved for Phase III trials or other developments that the EAU’s Scientific Congress Office believes will have a large impact on daily practice.

In addition, presentations will report on the potential utility of TLX250-CDx in urothelial carcinoma or bladder cancer (ZiPUP study, Identifier: NCT05046665); and a preclinical evaluation of a Telix targeted radionuclide therapy candidate in combination with an immune checkpoint inhibitor.

Dr Colin Hayward, Telix Chief Medical Officer, said, “In support of Telix’s vision to drive innovation in urologic oncology, we are pleased that our programs in renal and bladder cancer will be presented at EAU 2023, the largest urological event in Europe. Notably, Professor Peter Mulders from Radboud UMC will be presenting further data from the Phase III ZIRCON study of TLX250-CDx, our investigational renal cancer imaging agent, which is generating significant interest in the medical community, following a highly positive result. We are also excited to announce two additional presentations on Telix’s CAIX-targeting candidates further exploring potential theranostic applications beyond ccRCC.”

EAU presentation details are as follows:

Session: Game Changing Session

Title: 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma – results from phase 3 ZIRCON study

Date and Time: 11-Mar-2023, 10:00 AM-10:15 AM

Presenter: Prof. P.F.A. Mulders, Radboud UMC, Nijmegen, The Netherlands

Session: Clinical Trials in Progress

Title: 89 Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP) – A phase I trial of a novel staging modality for urothelial carcinoma

Date and Time: 12-Mar-2023, 10:45 AM-12:15 PM

Presenter: Dr. D. Hayne, University of Western Australia, Australia

Abstract ID: A0520

Session: Cell biology and novel biomarkers in kidney cancer

Title: Preclinical evaluation of targeted radionuclide therapy combined with immune checkpoint inhibition

Date and Time: 13-Mar-2023, 10:45 AM-12:15 PM

Presenter: Ass. Prof. E. Oosterwijk, Radboud UMC, Nijmegen, The Netherlands

Abstract ID: A1032

To read the the full media release, click here

For more information on EAU, including how to register, visit: